Industry Outlook

The Allergic Rhinitis Drug Market is estimated to expand to USD 19.3 Billion by 2035, showcasing a robust CAGR of 3.85% and starting from a valuation of USD 12.8 Billion in 2024. Allergic rhinitis, also called hay fever, refers to an allergic reaction caused by increased sensitivity to allergens in the surrounding environment of the patients. The individual suffers from a runny or stuffy nose, constant sneezing, swelling & redness around the eyes, and watery eyes. The increased amount of pollen in the environment has been seen as one of the most common causes of this allergic reaction. Allergic Rhinitis Market Size was valued at USD xx Billion in 2023. The surge in demand for effective and potent drugs among consumers across the globe is one of the major factors driving the market growth. The increase in the prevalence of various allergic rhinitis, including seasonal allergic rhinitis, perennial allergic rhinitis, and occupational allergic rhinitis among the population, and the rise in government initiatives to promote awareness regarding allergic rhinitis accelerate the market growth. 

Report Scope:

Market Dynamics

Increase spending towards healthcare disease to boost market growth

Over the past few decades, it has been noted that spending on health diseases has increased. This raises the awareness that different therapies are available to treat different ailments. This increase in healthcare costs has increased the demand for high-quality medicines and the fastest diagnostic methods for rapid recovery from any illness. For this reason, the demand for allergic rhinitis medicines in the market will grow, which will help drive the growth of the market in the coming years. Other important factors driving the growth of the allergic rhinitis medicines market are medical expenses, high demand for new technology investment, increasing diagnostic methods to treat various diseases, and increasing awareness of treatment availability during the forecast period.

Side Effects Lead to Deterrence from Medication Compliance

A notable restraining factor for this market is the prevalence of side effects linked to these medications. Common side effects, including drowsiness, dry mouth, blurred vision, headaches, and various other discomforts, can dissuade individuals from either starting or maintaining their prescribed treatment regimens. These concerns about side effects may lead some to avoid allergy rhinitis drugs altogether, even when necessary, or prompt premature discontinuation of medication, potentially resulting in the recurrence of allergy symptoms and affecting the market's growth.

 Increase in R&D of new therapies to shape the market growth.

An increase in R&D of new therapies is an emerging trend shaping market growth. Allergic rhinitis, a healthcare disease characterized by sneezing, swelling, watery eyes, and nasal congestion, is a global concern with increasing prevalence. This inflammatory response to allergens, such as pollen, tobacco, animal dander, or dust, can lead to more severe respiratory diseases like asthma. Corporate workers and individuals with cervical injuries from vehicle accidents are particularly susceptible to occupational allergens and stress. Researchers are exploring new strategies for medicines to manage allergic rhinitis. For instance, an immunomodulatory peptide drug discovered at Aarhus University blocks the immune effect behind allergic reactions by inactivating specific antibodies and removing immunoglobulin E molecules. This breakthrough offers new possibilities for pharmacological approaches. Diagnostic methods are essential for identifying allergic rhinitis types, including seasonal, perennial, and occupational. Over-the-counter medications like antihistamines, corticosteroids, and decongestants provide temporary relief, but long-term use may cause side effects.

Industry Experts Opinion

“Advancements in biologics and immunotherapy are expected to transform the treatment landscape by providing more targeted and personalized solutions."

• Prof. James O’Connor

"The growing interest in non-sedative antihistamines and combination therapies reflects the market’s shift towards improving patient compliance and quality of life."

• Dr. Emily Wang

Segment Analysis

Based on the Type: The allergic rhinitis market segmentation, based on type, includes seasonal allergic rhinitis, perennial allergic rhinitis, and occupational allergic rhinitis. The seasonal Allergic Rhinitis segment held the majority share in 2021 concerning the allergic rhinitis market revenue. This is primarily owing to the rising awareness about allergic rhinitis and the high usage of tobacco across the globe. Pollen is the most common allergen in seasonal allergic rhinitis. Mold, animal dander, and dust are the other substances that can cause allergic rhinitis. In November 2021, Revolo Biotherapeutics, a biotherapeutics company, started a phase II clinical trial for IRL201104, a novel immunomodulatory peptide drug indicated for seasonal allergic rhinitis. The study is expected to be completed in February 2023.

Based on By Route of Administration: The market of allergic rhinitis has been bifurcated by Route of Administration into Oral, Nasal & Others. The nasal & other route of administration segment dominated the market in 2021 and is projected to be the fastest-growing segment during the forecast period, 2022-2030. The market is estimated to grow owing to the quality of drugs and nasal sprays manufactured by manufacturers for the effective treatment of allergic rhinitis. In May 2021, Glenmark Pharma launched its nasal spray Ryaltris, used for the treatment of moderate to severe allergic rhinitis, in India. This initiative has further broadened the growth opportunity for the Allergic Rhinitis industry. 

Regional Analysis

North America leads the allergic rhinitis market for a variety of compelling reasons. It benefits from the presence of large pharmaceutical companies, which provide convenient access to cutting-edge treatment alternatives such as new medications and innovative delivery techniques. This infrastructure promotes constant innovation and guarantees that patients have access to the most recent advances in allergy therapy. The region’s high healthcare expenditure demonstrates a strong commitment to disease management. This financial commitment demonstrates a strong healthcare system that promotes research, development, and implementation of viable allergy treatment options. As a result, both healthcare providers and patients are more likely to accept and invest in new treatments, creating a dynamic market environment. North America has a considerable burden of allergic rhinitis, which is fueled by a high incidence of allergies and growing public awareness of its consequences. This combination creates an increasing desire for dependable and efficient treatments to relieve symptoms and improve quality of life. As knowledge grows and healthcare resources develop, North America is positioned to maintain its leadership in allergy care and treatment options.

The Asia Pacific region’s allergic rhinitis market to growing rapidly. Its growing population, particularly in developing countries with rising healthcare infrastructures, increases the need for better allergy control options. As these countries’ economies rise and healthcare access improves, more people seek out and can afford modern treatments for allergic rhinitis. Rising disposable incomes among the region’s population have an important impact. Consumers have a higher ability to prioritize health expenses, such as medications and therapies for managing allergy disorders, as their economic status grows. This economic empowerment drives market expansion by increasing the adoption of pharmaceutical items and healthcare services designed to treat allergic rhinitis. Environmental factors such as rising pollution levels are largely contributing to the increase in allergic rhinitis instances in Asia Pacific. As people become more aware of the effects of pollution on respiratory health, they are better able to recognize and diagnose allergy disorders. This awareness, combined with proactive initiatives to enhance air quality and limit allergen exposure, is likely to drive additional market growth as people look for effective ways to relieve symptoms and improve their quality of life.  

Competitive Landscape

The major players in the market are Merck KGaA, GSK group of companies, Sanofi, Cigna, Himalaya Wellness, Janssen Pharmaceuticals, Inc., FAES Farma SA, Hisamitsu Pharmaceutical Co., Inc., Glenmark Pharmaceuticals, Olainfarm, Boehringer Ingelheim International GmbH, Covis Pharma, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, ALK-Abello A/S, Meda AB, and Bayer AG.

ALK-Abelló A/S is a Denmark-based pharmaceutical company that specializes in the development and manufacture of allergy immunotherapy products for the prevention and treatment of allergy. In March 2021, ALK-Abelló A/S, a pharmaceutical company, announced its submission of a registration application in China, under National Medical Products Administration (NMPA), the Chinese agency for regulating drugs and medical devices, for its ACARIZAX, a house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet. In June 2019, ALK announced the successful marketing of sublingual allergy immunotherapy (SLIT) tablets in 17 European countries.

Also, Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India. Its portfolio of differentiated medicines in respiratory, dermatology, and oncology are acclaimed as breakthrough solutions for a wide range of diseases.  In February 2020, Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, and Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals, a global innovative pharmaceutical company, announced the signing of an exclusive US license agreement to commercialize Ryaltris, an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR).

Allergic Rhinitis Drug Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In June 2021, Bayer AG announced that it received FDA approval for Astepro® Allergy (Azelastine HCI .15%) as an over-the-counter (OTC) product for the temporary relief of nasal congestion, runny nose, sneezing, and itchy nose due to hay fever or other upper respiratory allergies. This has helped the company to expand its product portfolio.
• In July 2021, GlaxoSmithKline plc (GSK) announced that it received FDA approval for Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis. This has helped the company to expand its product portfolio.

Report Coverage:

By Treatment Type

• Antihistamines
• Immunotherapy
  • Subcutaneous Immunotherapy (SCIT)
  • Sublingual Immunotherapy (SLIT)
• Corticosteroids
• Decongestants
• Others

By Disease Type

• Seasonal Allergic Rhinitis
• Perennial Allergic Rhinitis
• Occupational Allergic Rhinitis

By Drug

• Prescription
• OTC

By Route of Administration

• Oral
• Nasal
• Intraocular
• Intravenous

By Distribution channel

• Hospital pharmacies
• Retail pharmacies
• Online channels

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Adamis Pharmaceuticals
• Alcon
• AstraZeneca
• Bayer AG
• Boehringer Ingelheim
• Dr Reddy's Laboratories
• GlaxoSmithKline PLC
• Innovus Pharmaceuticals, Inc.
• Johnson & Johnson
• Meda AB
• Merck & Co
• Mylan NV
• Sanofi S.A.
• Sun Pharmaceuticals
• Teva Pharmaceutical Industries Ltd
• Unichem Laboratories

Frequently Asked Questions (FAQs)